Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Swedes Explain Why They Should Have the EMA ‘Gem’ After Brexit

Executive Summary

Sweden explains the reasons why the European Medicines Agency should move there from London once the UK leaves the EU, citing an established life sciences network, a strong R&D sector, and a solid biopharmaceutical industry base.


Related Content

‘Virtually Bribery And Corruption Free’ Denmark With Its Clean Canals Says ‘Give Us EMA’
EMA Post-Brexit: 'It Can’t Stay In The UK' … Or Can It?
Dublin The Odds: Ireland Plays On Strengths As It Prepares EMA Bid





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst